JP2024023189A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024023189A5 JP2024023189A5 JP2023183500A JP2023183500A JP2024023189A5 JP 2024023189 A5 JP2024023189 A5 JP 2024023189A5 JP 2023183500 A JP2023183500 A JP 2023183500A JP 2023183500 A JP2023183500 A JP 2023183500A JP 2024023189 A5 JP2024023189 A5 JP 2024023189A5
- Authority
- JP
- Japan
- Prior art keywords
- mutation
- cancer
- stage
- ras
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102200006538 rs121913530 Human genes 0.000 claims description 17
- 230000035772 mutation Effects 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000001404 mediated effect Effects 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 4
- 101710113436 GTPase KRas Proteins 0.000 claims 10
- 239000003814 drug Substances 0.000 claims 8
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 7
- 206010009944 Colon cancer Diseases 0.000 claims 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 6
- 201000005202 lung cancer Diseases 0.000 claims 6
- 208000020816 lung neoplasm Diseases 0.000 claims 6
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 206010023774 Large cell lung cancer Diseases 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000009546 lung large cell carcinoma Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 101150105104 Kras gene Proteins 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024187827A JP2025026853A (ja) | 2018-11-09 | 2024-10-25 | 縮合環化合物 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/114788 | 2018-11-09 | ||
| CN2018114788 | 2018-11-09 | ||
| JP2020542808A JP6941241B2 (ja) | 2018-11-09 | 2019-11-08 | 縮合環化合物 |
| JP2021116809A JP7374960B2 (ja) | 2018-11-09 | 2021-07-15 | 縮合環化合物 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021116809A Division JP7374960B2 (ja) | 2018-11-09 | 2021-07-15 | 縮合環化合物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187827A Division JP2025026853A (ja) | 2018-11-09 | 2024-10-25 | 縮合環化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024023189A JP2024023189A (ja) | 2024-02-21 |
| JP2024023189A5 true JP2024023189A5 (https=) | 2024-05-31 |
| JP7579414B2 JP7579414B2 (ja) | 2024-11-07 |
Family
ID=69232886
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542808A Active JP6941241B2 (ja) | 2018-11-09 | 2019-11-08 | 縮合環化合物 |
| JP2021116809A Active JP7374960B2 (ja) | 2018-11-09 | 2021-07-15 | 縮合環化合物 |
| JP2023183500A Active JP7579414B2 (ja) | 2018-11-09 | 2023-10-25 | 縮合環化合物 |
| JP2024187827A Pending JP2025026853A (ja) | 2018-11-09 | 2024-10-25 | 縮合環化合物 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542808A Active JP6941241B2 (ja) | 2018-11-09 | 2019-11-08 | 縮合環化合物 |
| JP2021116809A Active JP7374960B2 (ja) | 2018-11-09 | 2021-07-15 | 縮合環化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024187827A Pending JP2025026853A (ja) | 2018-11-09 | 2024-10-25 | 縮合環化合物 |
Country Status (33)
| Country | Link |
|---|---|
| US (3) | US11236068B2 (https=) |
| EP (2) | EP4483881A3 (https=) |
| JP (4) | JP6941241B2 (https=) |
| KR (3) | KR20250012188A (https=) |
| CN (5) | CN112105419B (https=) |
| AR (1) | AR117194A1 (https=) |
| AU (3) | AU2019377130B2 (https=) |
| BR (1) | BR112021008986A2 (https=) |
| CA (1) | CA3087089C (https=) |
| CL (2) | CL2021001171A1 (https=) |
| CO (1) | CO2021005987A2 (https=) |
| CR (1) | CR20210229A (https=) |
| DK (1) | DK3735299T3 (https=) |
| ES (1) | ES3004042T3 (https=) |
| FI (1) | FI3735299T3 (https=) |
| HR (1) | HRP20241581T1 (https=) |
| HU (1) | HUE069365T2 (https=) |
| IL (3) | IL282916B2 (https=) |
| LT (1) | LT3735299T (https=) |
| MA (1) | MA51530B1 (https=) |
| MX (5) | MX2021005428A (https=) |
| MY (1) | MY196726A (https=) |
| PE (2) | PE20260440A1 (https=) |
| PH (1) | PH12021551065A1 (https=) |
| PL (1) | PL3735299T3 (https=) |
| PT (1) | PT3735299T (https=) |
| RS (1) | RS66280B1 (https=) |
| SG (1) | SG11202103298QA (https=) |
| SI (1) | SI3735299T1 (https=) |
| SM (1) | SMT202400487T1 (https=) |
| TW (2) | TWI883352B (https=) |
| UA (1) | UA127930C2 (https=) |
| WO (1) | WO2020097537A2 (https=) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210006356A (ko) | 2018-04-04 | 2021-01-18 | 아비나스 오퍼레이션스, 인코포레이티드 | 단백질분해 조절제 및 연관된 사용 방법 |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| CN118359609A (zh) | 2019-05-21 | 2024-07-19 | 益方生物科技(上海)股份有限公司 | 杂环化合物，其制备方法和用途 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN114867726B (zh) | 2019-10-28 | 2023-11-28 | 默沙东有限责任公司 | Kras g12c突变体的小分子抑制剂 |
| EP4065231A1 (en) * | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| US12479834B2 (en) | 2019-11-29 | 2025-11-25 | Taiho Pharmaceutical Co., Ltd. | Phenol compound or salt thereof |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| TWI829003B (zh) * | 2020-08-12 | 2024-01-11 | 美商建南德克公司 | 喹唑啉化合物之合成 |
| CN115956080B (zh) * | 2020-08-17 | 2025-07-11 | 贝达药业股份有限公司 | 双环化合物，包含其的组合物及其应用 |
| CN116368130A (zh) | 2020-08-28 | 2023-06-30 | 金橘生物科技公司 | 杂环化合物及其用途 |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| WO2022056307A1 (en) | 2020-09-11 | 2022-03-17 | Mirati Therapeutics, Inc. | Crystalline forms of a kras g12c inhibitor |
| AU2021347232A1 (en) | 2020-09-23 | 2023-04-27 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| US20230365563A1 (en) * | 2020-09-30 | 2023-11-16 | Shanghai Pharmaceuticals Holding Co., Ltd. | Quinazoline compound and application thereof |
| WO2022098625A1 (en) * | 2020-11-03 | 2022-05-12 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| US12171763B2 (en) * | 2020-11-13 | 2024-12-24 | Genentech, Inc. | Methods and compositions comprising a KRASG12C inhibitor and a PD-L1 binding antagonist for treating lung cancer |
| CN116568326A (zh) * | 2020-11-13 | 2023-08-08 | 基因泰克公司 | 用于治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物 |
| UY39526A (es) * | 2020-11-20 | 2022-06-30 | Jacobio Pharmaceuticals Co Ltd | Inhibidores de kras g12d |
| WO2022105855A1 (en) * | 2020-11-20 | 2022-05-27 | Jacobio Pharmaceuticals Co., Ltd. | Kras g12d inhibitors |
| IL303448A (en) * | 2020-12-08 | 2023-08-01 | Genentech Inc | Methods and compositions including a KRASG12C inhibitor and an EGFR inhibitor for the treatment of solid tumors |
| WO2022132200A1 (en) | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| US20240109893A1 (en) * | 2020-12-22 | 2024-04-04 | Shanghai Kechow Pharma, Inc. | Preparation and application method of heterocyclic compounds as kras inhibitor |
| CN113999226B (zh) * | 2020-12-22 | 2023-01-06 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物的制备及其应用方法 |
| CN114685532A (zh) * | 2020-12-31 | 2022-07-01 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| WO2022173870A1 (en) * | 2021-02-09 | 2022-08-18 | Kumquat Biosciences Inc. | Heterocyclic compounds and uses thereof |
| WO2022171018A1 (zh) * | 2021-02-09 | 2022-08-18 | 苏州泽璟生物制药股份有限公司 | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 |
| WO2022171013A1 (zh) * | 2021-02-09 | 2022-08-18 | 南京明德新药研发有限公司 | 四氢喹唑啉类化合物 |
| CA3210167A1 (en) * | 2021-02-09 | 2022-08-18 | Genentech, Inc. | Tetracyclic oxazepine compounds and uses thereof |
| AU2022224511A1 (en) * | 2021-02-16 | 2023-08-10 | Lawrence Livermore National Security, Llc | Compositions and methods for inhibition of ras |
| WO2022214102A1 (zh) * | 2021-04-09 | 2022-10-13 | 杭州英创医药科技有限公司 | 作为kras g12d抑制剂的杂环化合物 |
| WO2022221386A1 (en) * | 2021-04-14 | 2022-10-20 | Erasca, Inc. | Selective kras inhibitors |
| WO2022221739A1 (en) * | 2021-04-16 | 2022-10-20 | Merck Sharp & Dohme Corp. | Small molecule inhibitors of kras g12d mutant |
| JP2024517695A (ja) * | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | 複素環式化合物及び使用方法 |
| WO2022235866A1 (en) * | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| CN117337193A (zh) * | 2021-05-19 | 2024-01-02 | 基因泰克公司 | 组合疗法 |
| WO2022247760A1 (zh) * | 2021-05-22 | 2022-12-01 | 上海科州药物研发有限公司 | 作为kras抑制剂的杂环化合物，及其制备和治疗用途 |
| US20240261444A1 (en) * | 2021-05-26 | 2024-08-08 | Cornell University | Rigidified macrocycles, complexes with radionuclides, and use in targeted radiotherapy of cancer |
| EP4373822A2 (en) | 2021-07-23 | 2024-05-29 | Theras Inc. | Compositions and methods for inhibition of ras |
| CN117858878A (zh) * | 2021-08-18 | 2024-04-09 | 北京加科思新药研发有限公司 | N-环丙基吡啶并[4,3-d]嘧啶-4-胺衍生物及其用途 |
| TW202315626A (zh) * | 2021-08-31 | 2023-04-16 | 大陸商勁方醫藥科技(上海)有限公司 | 嘧啶并環類化合物及其製法和用途 |
| CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| EP4436957A1 (en) | 2021-11-24 | 2024-10-02 | Genentech, Inc. | Therapeutic indazole compounds and methods of use in the treatment of cancer |
| JP2024543879A (ja) * | 2021-11-24 | 2024-11-26 | メルク・シャープ・アンド・ドーム・エルエルシー | Ｋｒａｓ変異型タンパク質の小分子阻害剤 |
| TW202340212A (zh) | 2021-11-24 | 2023-10-16 | 美商建南德克公司 | 治療性化合物及其使用方法 |
| US20250059187A1 (en) | 2021-12-22 | 2025-02-20 | The Regents Of The University Of California | Covalently binding inhibitors of g12s, g12d and/or g12e mutants of k-ras gtpase |
| WO2023133183A1 (en) * | 2022-01-06 | 2023-07-13 | Theras, Inc. | Kras inhibitors |
| AR128212A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| JP2025505655A (ja) * | 2022-02-07 | 2025-02-28 | ジェネンテック， インコーポレイテッド | １－（（ｓ）－４－（（ｒ）－７－（６－アミノ－４－メチル－３－（トリフルオロメチル）ピリジン－２－イル）－６－クロロ－８－フルオロ－２－（（（ｓ）－１－メチルピロリジン－２－イル）メトキシ）キナゾリン－４－イル）－３－メチルピペラジン－１－イル）プロパ－２－エン－１－オンの固体形態 |
| WO2023150653A1 (en) * | 2022-02-07 | 2023-08-10 | Genentech, Inc. | Process for synthesis of quinazoline compounds |
| KR20240163107A (ko) | 2022-03-11 | 2024-11-18 | 컴쿼트 바이오사이언시즈 인크. | 헤테로환 화합물 및 이의 용도 |
| US20250177406A1 (en) | 2022-03-31 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| EP4504202B1 (en) * | 2022-04-06 | 2026-02-04 | Genentech Inc. | Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer |
| TW202400170A (zh) | 2022-05-19 | 2024-01-01 | 美商建南德克公司 | 氮雜－四環氧氮呯化合物及其用途 |
| CN115043729B (zh) * | 2022-07-04 | 2024-09-27 | 青岛大学 | 一种2,2’-二氟联芳基化合物的不对称合成方法 |
| CA3261681A1 (en) | 2022-08-05 | 2024-02-08 | Kumquat Biosciences Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| EP4568952A1 (en) | 2022-08-11 | 2025-06-18 | Bristol-Myers Squibb Company | Kras inhibitors |
| EP4573095A1 (en) | 2022-08-17 | 2025-06-25 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| WO2024081674A1 (en) | 2022-10-11 | 2024-04-18 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| WO2024112654A1 (en) | 2022-11-21 | 2024-05-30 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| CN115920658B (zh) * | 2023-01-15 | 2023-10-20 | 安徽科博瑞环境科技有限公司 | 低表面能抗污染中空纤维膜及其制备方法 |
| WO2024153119A1 (en) * | 2023-01-18 | 2024-07-25 | Suzhou Zanrong Pharma Limited | Kras g12d inhibitors and uses thereof |
| EP4655298A1 (en) * | 2023-01-24 | 2025-12-03 | Theras Inc. | Compositions and methods for inhibition of ras |
| CN121419983A (zh) | 2023-01-26 | 2026-01-27 | 阿尔维纳斯运营股份有限公司 | 基于小脑蛋白的kras降解protac及其相关用途 |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| JPWO2024209717A1 (https=) | 2023-04-06 | 2024-10-10 | ||
| CN116396202A (zh) * | 2023-04-17 | 2023-07-07 | 南京优氟医药科技有限公司 | 一种（2s，4s）-4-氟代吡咯烷-2-羧酸的制备方法 |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| CN121605110A (zh) | 2023-06-06 | 2026-03-03 | 金橘生物科技公司 | 取代杂环化合物及其用途 |
| US20250000802A1 (en) | 2023-06-09 | 2025-01-02 | Hoffmann-La Roche Inc. | Solid formulations comprising an inhibitor of the k-ras protein having a g12c mutation, and a process for preparing |
| WO2025010415A1 (en) * | 2023-07-05 | 2025-01-09 | The Regents Of The University Of California | Gtpase inhibitors and uses thereof |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| TW202528315A (zh) | 2023-09-21 | 2025-07-16 | 美商樹線生物科學公司 | 螺環二氫哌喃并吡啶ＫＲａｓ抑制劑 |
| TW202529768A (zh) | 2023-09-29 | 2025-08-01 | 大陸商德昇濟醫藥（無錫）有限公司 | 癌症治療的療法 |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025085748A1 (en) | 2023-10-20 | 2025-04-24 | Merck Sharp & Dohme Llc | Small molecule inhibitors of kras proteins |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025245127A1 (en) | 2024-05-21 | 2025-11-27 | Treeline Biosciences, Inc. | Spirocyclic dihydropyranopyrimidine kras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999002557A1 (en) | 1997-07-11 | 1999-01-21 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V | Novel pharmaceutically active compounds interacting with gtp-binding proteins |
| EP2288260A4 (en) | 2008-06-20 | 2013-10-23 | Genentech Inc | TRIAZOLOPYRIDINE-JAK HEMMER COMPOUNDS AND METHOD |
| EP2836482B1 (en) | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| AU2014331794C1 (en) * | 2013-10-10 | 2019-09-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C |
| TWI659021B (zh) | 2013-10-10 | 2019-05-11 | 亞瑞克西斯製藥公司 | Ｋｒａｓ ｇ１２ｃ之抑制劑 |
| JO3556B1 (ar) * | 2014-09-18 | 2020-07-05 | Araxes Pharma Llc | علاجات مدمجة لمعالجة السرطان |
| ES2826443T3 (es) | 2014-09-25 | 2021-05-18 | Araxes Pharma Llc | Inhibidores de proteínas mutantes KRAS G12C |
| US10011600B2 (en) | 2014-09-25 | 2018-07-03 | Araxes Pharma Llc | Methods and compositions for inhibition of Ras |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| US10144724B2 (en) | 2015-07-22 | 2018-12-04 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use thereof |
| JP2018533939A (ja) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Ｒａｓの阻害剤をスクリーニングするための方法 |
| KR20180081596A (ko) | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| JP7039489B2 (ja) * | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| US10646488B2 (en) | 2016-07-13 | 2020-05-12 | Araxes Pharma Llc | Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof |
| JP2020521741A (ja) | 2017-05-25 | 2020-07-27 | アラクセス ファーマ エルエルシー | がんの処置のための化合物およびその使用の方法 |
| US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
| AU2018271990A1 (en) | 2017-05-25 | 2019-12-12 | Araxes Pharma Llc | Covalent inhibitors of KRAS |
| HRP20230377T1 (hr) | 2017-11-15 | 2023-06-23 | Mirati Therapeutics, Inc. | Inhibitori mutacije kras g12c |
| SG11202005547YA (en) | 2017-12-19 | 2020-07-29 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| TW201942115A (zh) | 2018-02-01 | 2019-11-01 | 美商輝瑞股份有限公司 | 作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物 |
-
2019
- 2019-11-08 PT PT198428484T patent/PT3735299T/pt unknown
- 2019-11-08 HU HUE19842848A patent/HUE069365T2/hu unknown
- 2019-11-08 CR CR20210229A patent/CR20210229A/es unknown
- 2019-11-08 IL IL282916A patent/IL282916B2/en unknown
- 2019-11-08 HR HRP20241581TT patent/HRP20241581T1/hr unknown
- 2019-11-08 WO PCT/US2019/060578 patent/WO2020097537A2/en not_active Ceased
- 2019-11-08 KR KR1020257000144A patent/KR20250012188A/ko active Pending
- 2019-11-08 EP EP24198360.0A patent/EP4483881A3/en active Pending
- 2019-11-08 CN CN201980026181.6A patent/CN112105419B/zh active Active
- 2019-11-08 PE PE2025003077A patent/PE20260440A1/es unknown
- 2019-11-08 PE PE2021000682A patent/PE20211504A1/es unknown
- 2019-11-08 JP JP2020542808A patent/JP6941241B2/ja active Active
- 2019-11-08 ES ES19842848T patent/ES3004042T3/es active Active
- 2019-11-08 DK DK19842848.4T patent/DK3735299T3/da active
- 2019-11-08 KR KR1020207024122A patent/KR102587544B1/ko active Active
- 2019-11-08 IL IL311187A patent/IL311187B2/en unknown
- 2019-11-08 AU AU2019377130A patent/AU2019377130B2/en active Active
- 2019-11-08 UA UAA202101478A patent/UA127930C2/uk unknown
- 2019-11-08 US US16/679,104 patent/US11236068B2/en active Active
- 2019-11-08 RS RS20241331A patent/RS66280B1/sr unknown
- 2019-11-08 SG SG11202103298QA patent/SG11202103298QA/en unknown
- 2019-11-08 AR ARP190103302A patent/AR117194A1/es unknown
- 2019-11-08 LT LTEPPCT/US2019/060578T patent/LT3735299T/lt unknown
- 2019-11-08 CA CA3087089A patent/CA3087089C/en active Active
- 2019-11-08 CN CN202410280860.9A patent/CN118084866A/zh active Pending
- 2019-11-08 MA MA51530A patent/MA51530B1/fr unknown
- 2019-11-08 TW TW111140273A patent/TWI883352B/zh active
- 2019-11-08 SM SM20240487T patent/SMT202400487T1/it unknown
- 2019-11-08 CN CN202410281087.8A patent/CN118084870A/zh active Pending
- 2019-11-08 PL PL19842848.4T patent/PL3735299T3/pl unknown
- 2019-11-08 BR BR112021008986-1A patent/BR112021008986A2/pt unknown
- 2019-11-08 SI SI201930862T patent/SI3735299T1/sl unknown
- 2019-11-08 CN CN202410280943.8A patent/CN118084867A/zh active Pending
- 2019-11-08 FI FIEP19842848.4T patent/FI3735299T3/fi active
- 2019-11-08 MY MYPI2021002582A patent/MY196726A/en unknown
- 2019-11-08 EP EP19842848.4A patent/EP3735299B1/en active Active
- 2019-11-08 TW TW108140719A patent/TWI784209B/zh active
- 2019-11-08 KR KR1020237033977A patent/KR102751492B1/ko active Active
- 2019-11-08 MX MX2021005428A patent/MX2021005428A/es unknown
- 2019-11-08 CN CN202410281112.2A patent/CN118084868A/zh active Pending
-
2021
- 2021-05-04 CL CL2021001171A patent/CL2021001171A1/es unknown
- 2021-05-07 MX MX2025002975A patent/MX2025002975A/es unknown
- 2021-05-07 CO CONC2021/0005987A patent/CO2021005987A2/es unknown
- 2021-05-07 PH PH12021551065A patent/PH12021551065A1/en unknown
- 2021-05-07 MX MX2024008118A patent/MX2024008118A/es unknown
- 2021-05-07 MX MX2025002979A patent/MX2025002979A/es unknown
- 2021-05-07 MX MX2025002980A patent/MX2025002980A/es unknown
- 2021-07-15 JP JP2021116809A patent/JP7374960B2/ja active Active
- 2021-12-17 US US17/644,993 patent/US12084429B2/en active Active
-
2022
- 2022-03-01 AU AU2022201413A patent/AU2022201413B9/en active Active
- 2022-03-22 CL CL2022000698A patent/CL2022000698A1/es unknown
-
2023
- 2023-10-25 JP JP2023183500A patent/JP7579414B2/ja active Active
-
2024
- 2024-02-13 AU AU2024200904A patent/AU2024200904B2/en active Active
- 2024-06-18 US US18/747,054 patent/US20250059163A1/en active Pending
- 2024-10-25 JP JP2024187827A patent/JP2025026853A/ja active Pending
-
2025
- 2025-10-20 IL IL324078A patent/IL324078A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023189A5 (https=) | ||
| US20220387384A1 (en) | Methods of treating lsd1-related diseases and disorders with lsd1 inhibitors | |
| JP2025020147A5 (https=) | ||
| CN101001623B (zh) | 抗癌效果增强剂 | |
| JPWO2021121367A5 (https=) | ||
| JP2009538327A5 (https=) | ||
| JPWO2022269525A5 (https=) | ||
| Lee et al. | A 10-year update of CHOP-Bleo in the treatment of diffuse large-cell lymphoma. | |
| TW202329946A (zh) | 用於治療癌症之方法及包含cdk2抑制劑之給藥方案 | |
| CN107773556A (zh) | 一种具有抗肿瘤药物功效的联合用药物 | |
| Homma et al. | Successful treatment of refractory bronchorrhea by inhaled indomethacin in two patients with bronchioloalveolar carcinoma | |
| JP2025509278A (ja) | 小細胞肺癌を治療する方法 | |
| Nelson et al. | Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer | |
| JPWO2021263026A5 (https=) | ||
| JPWO2022170060A5 (https=) | ||
| TW202120085A (zh) | 抗ccr4抗體抵抗性之癌症的治療劑 | |
| JPWO2023010121A5 (https=) | ||
| Liu et al. | Low dose of apatinib in treating chemotherapy and EGFR-TKI refractory non-small cell lung cancer: a case report | |
| Wei et al. | Pulmonary Toxicity Associated With Concurrent Lorlatinib and Anti‐GD2 Monoclonal Antibody Therapy in Patients With Neuroblastoma | |
| RU2826217C1 (ru) | Способы лечения заболеваний и нарушений, связанных с lsd1, ингибиторами lsd1 | |
| CN114558023B (zh) | 长梗冬青苷在制备抑制肺转移癌的药物中的应用 | |
| JP5865896B2 (ja) | 胃癌を処置する方法 | |
| Andayani et al. | Remarkable Breakthrough: Unleashing the Power of Paclitaxel and Carboplatin in Defeating Squamous Cell Carcinoma (SCC) of the Lungs-A Compelling Case Report | |
| Zhang et al. | P2. 01-119 Phase III Randomized Trial of Palonosetron and Dexamethasone with Aprepitant to Prevent Full Dose Single-Day Cisplatin-Based CINV in Lung Cancer | |
| Lin et al. | P35. 12 Assessment of Molecular Heterogeneity in Multiple Primary Lung Cancer Patients by Whole-Exome Sequencing |